NCT03882424View on ClinicalTrials.gov

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

PHASE1CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

September 30, 2018

Study Completion Date

October 25, 2018

Conditions

Healthy

Interventions

BIOLOGICAL

TRS003

25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes

BIOLOGICAL

China-approved Bevacizumab

25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes

BIOLOGICAL

US-licensed Avastin

25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes

Trial Locations (1)

90630

WCCT Global, Inc., Cypress

All Listed Sponsors

lead

Zhejiang Teruisi Pharmaceutical Inc.

INDUSTRY

NCT03882424 - A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin® | Biotech Hunter | Biotech Hunter